Cap $30m and last year they lost $24.5m - serious stuff. What...

Cap $30m and last year they lost $24.5m - serious stuff. What indignation would be, numerous $100m offers for their drug, immediately, post their ASX listing. That is xactly what could happen.

- effective inhibition of the abrogated PI3K/AKT/mTOR pathway in up to 70%  of ALL CANCERS-  in multiple drug combinations, could be the much sought after, curative to cancer. That is the potential of the drug owned by this company Kazia Therapeutics.

Investor extreme frustration at this situation - you bet.

New strategies and changes need to be made immediately.  Here are some suggestions :

1/. Immediate advice of cessation of the ATM fund raising program.

2/. Revisit the Memorial Sloan Kettering results. Present the company maker slide, from MSK Dr Yang - suggesting paxalisb is superior to current approved drugs.

3/. Specifically confirm via the ASX - that a licensing deal is currently being negotiated.

4/. Reach out to apparent top 5 shareholder, who is a current seller of their share holding.

5/. Make specific and direct contact with 20 US private equity funds, already invested in cancer startups. (I can provide those names, if requested by the company)

6/. An exit plan and board changes next year - formal advice via ASX.

7/. Cessation of company bonus and incentive plans for 2023.

-----------------------------------------------------

The mood of investors can change here quickly - if it was known a deal was around the corner - and some, even veiled acknowledgement, that changes need to be made, and are being made.

What is the alternative if this course of action is not taken - a conservative Chairman here.  Serious alright.